Edition:
United Kingdom

Resverlogix Corp (RVX.TO)

RVX.TO on Toronto Stock Exchange

3.11CAD
7 Dec 2018
Change (% chg)

-- (--)
Prev Close
$3.11
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
82,932
52-wk High
$4.31
52-wk Low
$1.11

Latest Key Developments (Source: Significant Developments)

Resverlogix Says Intends To Pursue U.S. Listing
Tuesday, 31 Jul 2018 

July 31 (Reuters) - Resverlogix Corp ::RESVERLOGIX INTENDS TO PURSUE U.S. LISTING.RESVERLOGIX - INTENDS TO REQUEST SHAREHOLDER APPROVAL FOR CONSOLIDATION OF CO'S COMMON SHARES AT ANNUAL & SPECIAL MEETING OF SHAREHOLDERS OF CO.RESVERLOGIX CORP - COMPANY'S COMMON SHARES AND WARRANTS WOULD CONTINUE TO BE LISTED ON TORONTO STOCK EXCHANGE.  Full Article

Resverlogix Receives FDA Protocol Acceptance For Ongoing Phase 3 Betonmace Trial
Thursday, 11 Jan 2018 

Jan 11 (Reuters) - Resverlogix Corp ::RESVERLOGIX RECEIVES FDA PROTOCOL ACCEPTANCE FOR THE ONGOING PHASE 3 BETONMACE TRIAL.RESVERLOGIX CORP - BETONMACE TOP LINE DATA IS STILL PLANNED TO BE AVAILABLE AROUND END OF 2018.RESVERLOGIX - BETONMACE TRIAL WILL NOW BE EXPANDED TO NORTH AMERICA.  Full Article

Resverlogix, Medison Pharma Ltd Announce Strategic Licensing Agreement
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Resverlogix Corp ::RESVERLOGIX AND MEDISON PHARMA LTD. ANNOUNCE STRATEGIC LICENSING AGREEMENT.RESVERLOGIX CORP - ‍UNDER TERMS OF AGREEMENT, MEDISON HAS EXCLUSIVE RIGHTS TO DISTRIBUTE AND MARKET APABETALONE IN ISRAEL​.RESVERLOGIX CORP - CO IS ELIGIBLE TO RECEIVE FROM MEDISON, ASCENDING DOUBLE DIGIT ROYALTIES BASED ON FUTURE NET SALES OF PRODUCT IN REGION.RESVERLOGIX CORP - ENTERED LICENSING AGREEMENT WITH MEDISON PHARMA FOR CO'S LEAD THERAPEUTIC CANDIDATE, APABETALONE IN ISRAEL AND PALESTINE AUTHORITY.RESVERLOGIX CORP - MEDISON WILL BE RESPONSIBLE FOR ALL REGULATORY, SALES AND MARKETING COSTS FOR APABETALONE IN ISRAEL REGION.  Full Article

Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for Apabetalone
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Resverlogix Corp :Resverlogix announces fifth positive recommendation from Data Safety Monitoring Board for phase 3 study of Apabetalone.Resverlogix - ‍independent DSMB recommended phase 3 study of Apabetalone should continue as planned without modifications ​.Resverlogix Corp - ‍full enrollment for phase 3 study of apabetalone now anticipated in first half of 2018​.  Full Article

Resverlogix reports $87 mln private placement with Shenzhen Hepalink
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Resverlogix Corp ::Resverlogix announces $87 million private placement with shenzhen hepalink.Resverlogix Corp - ‍net proceeds of offering will primarily be used to repay company's $68.8 million secured loan which matures on December 26, 2017​.Resverlogix Corp - ‍ private placement of 60.4 million equity units to Shenzhen Hepalink Pharmaceutical Co. Ltd. At a price of $1.44 per unit​.Resverlogix-Proceeds will also be used to fund research,development activities for clinical trial activities related to phase 3 betonmace trial​.Resverlogix - ‍ placement to address co's financial difficulties by providing sufficient funds to repay loan and to satisfy short term cash requirements​.  Full Article

Shenzhen Hepalink Pharmaceutical to invest in Canada's Resverlogix Corp
Friday, 13 Oct 2017 

Oct 13 (Reuters) - Shenzhen Hepalink Pharmaceutical Co Ltd <002399.SZ>:Says it plans to invest up to C$87 million ($69.75 million) in Canada's Resverlogix Corp <<>>.  Full Article

Successful CANTOS Inflammation Trial supports rationale for Resverlogix' ongoing betonmace trial
Tuesday, 29 Aug 2017 

Aug 29 (Reuters) - Resverlogix Corp :under CANTOS trial treatment with Resverlogix' apabetalone has demonstrated a reduction in inflammatory mediator il-6 by 29 percent​.  Full Article